Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Netanasvir and Encofosbuvir in Healthy Subjects
NCT04232514Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of yimitasvir and encofosbuvir in hepatitis C (HCV) (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Adverse Events, Maximum Plasma Concentration and 1 more. Started Jul 2020; status: completed.
02
Drugs
yimitasvirencofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04232514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232514.